OrbiMed’s Seres Therapeutics MCRB Stock Holding History

OrbiMed’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,750	Closed	-$1.2M	–	141
2017 Q3	$1.2M	Buy	+3,750	New	+$1.02M	0.01%	132

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

OrbiMed's MCRB Position: Q2 2018 in Review

OrbiMed sold out of Seres Therapeutics (MCRB) in Q2 2018, closing a stake of 4,761 shares — an estimated $699K sold.

OrbiMed first reported a position in MCRB in Q2 2015 and held it in 8 quarters. The position peaked at $10.2M in Q2 2015. 78 funds tracked by Wall St. Rank hold MCRB as of Q2 2018.

OrbiMed reported no remaining Seres Therapeutics position as of Q2 2018 after selling out during the quarter.
OrbiMed sold 4,761 Seres Therapeutics shares in Q2 2018, an estimated $699K.
OrbiMed first reported a position in Seres Therapeutics in Q2 2015 and held it in 8 quarters.
OrbiMed's Seres Therapeutics position peaked at $10.2M in Q2 2015.
78 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2018.

Based on OrbiMed's 13F filing for Q2 2018, filed 14 Aug 2018.